Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group

Bai,Fugui; Yano,Yoshihiko; Kim,Soo-Ryang; Seo,Yasushi; Miki,Akira; Saito,Masaya; Hirano,Hirotaka; Momose,Kenji; Minami,Akihiro; Hatazawa,Yuri; Hayakumo,Takanobu; Widasari,Dewiyani Indah; Rinonce,Hanggoro Tri; Sugano,Masahiko; Tani,Satoshi; Yoon,Seitetsu; Imoto,Susumu; Azuma,Takeshi; Hotta,Hak; Hayashi,Yoshitake

doi:10.3892/ijmm.2014.1706

Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group

Authors:
- Fugui Bai
- Yoshihiko Yano
- Soo-Ryang Kim
- Yasushi Seo
- Akira Miki
- Masaya Saito
- Hirotaka Hirano
- Kenji Momose
- Akihiro Minami
- Yuri Hatazawa
- Takanobu Hayakumo
- Dewiyani Indah Widasari
- Hanggoro Tri Rinonce
- Masahiko Sugano
- Satoshi Tani
- Seitetsu Yoon
- Susumu Imoto
- Takeshi Azuma
- Hak Hotta
- Yoshitake Hayashi
View Affiliations

Affiliations: Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan, Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Hyogo 653-0801, Japan, Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan, Sugano Clinic, Himeji, Hyogo 671-0223, Japan, Division of Internal Medicine, Konan Hospital, Kobe, Hyogo 658-0064, Japan, Department of Gastroenterology, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo 675-8555, Japan
Published online on: March 19, 2014 https://doi.org/10.3892/ijmm.2014.1706
Pages: 1652-1656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Telaprevir, a non-structural (NS)3/4A protease inhibitor, is a direct-acting antiviral drug that inhibits viral replication. Triple therapy with telaprevir, pegylated interferon, and ribavirin is a standard therapeutic regimen for patients with genotype 1b chronic hepatitis C virus (HCV) infection and a high viral load. Several factors, including mutations in the NS5A gene, are important predictors of the efficacy of interferon therapy. In this study, we examined the mutational diversity of NS5A and its impact on the efficacy of triple therapy. We enrolled patients with genotype 1b chronic HCV infection and a high viral load (31 males/17 females; mean age, 57.6 years), who were treated with triple therapy. This study was conducted at Kobe University Hospital and at three affiliated hospitals in Hyogo prefecture, Japan, between November 2011 and June 2013. A sustained viral response after 12 weeks (SVR12) was achieved in 37/48 patients (77%). Based on intent-to-treat analysis, SVR12 was significantly greater in patients with the major allele than in those with the minor allele for the IL28B single nucleotide polymorphism (SNP; 88 vs. 56%; P<0.05). The prevalence of the V2334I mutation in NS5A was significantly higher in patients who achieved SVR12, while that of G2356E was significantly higher in patients who did not achieve SVR12 (P<0.05). Mutations in the NS3 region that are thought to confer resistance to telaprevir were detected in 3/27 patients who achieved SVR12 (Val36, n=3) and in 5/10 patients who did not achieve SVR12 (Val36, n=4; Thr54, n=1). In conclusion, the IL28B SNP and mutations in the NS5A region were associated with the therapeutic response to triple therapy. Half of the patients who did not achieve SVR12 had mutations conferring resistance to telaprevir. However, pre-existing mutations in NS3 did not affect the efficacy of triple therapy.

View Figures

View References

1	Seeff LB: Natural history of chronic hepatitis C. Hepatology. 36:S35–S46. 2002. View Article : Google Scholar : PubMed/NCBI
2	Lavanchy D: The global burden of hepatitis C. Liver Int. 29:74–81. 2009. View Article : Google Scholar
3	Hagiwara H, Hayashi N, Mita E, et al: Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology. 15:37–41. 1992. View Article : Google Scholar : PubMed/NCBI
4	National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology. 36(Suppl 1): S3–S20. 2002. View Article : Google Scholar : PubMed/NCBI
5	Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:975–982. 2002. View Article : Google Scholar : PubMed/NCBI
6	Tanaka Y, Nishida N, Sugiyama M, et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41:1105–1109. 2009. View Article : Google Scholar : PubMed/NCBI
7	Akuta N, Suzuki F, Kawamura Y, et al: Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and lowdensity lipoprotein cholesterol levels. J Hepatol. 46:403–410. 2007.
8	Enomoto N, Sakuma I, Asahina Y, et al: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:77–81. 1996. View Article : Google Scholar : PubMed/NCBI
9	El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR and Hotta H: Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 48:38–47. 2008. View Article : Google Scholar : PubMed/NCBI
10	McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J and Muir AJ; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 360:1827–1838. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sanjo M, Saito T, Ishii R, et al: Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol. 82:1364–1370. 2010. View Article : Google Scholar : PubMed/NCBI
12	Welsch C, Jesudian A, Zeuzem S and Jacobson I: New direct-acting antiviral agents for the treatment of hepatitis C virus infection and prospectives. Gut. 61(Suppl 1): i36–i46. 2012. View Article : Google Scholar : PubMed/NCBI
13	Jesudian AB, Gambarin-Gelwan M and Jacobson IM: Advances in the treatment of hepatitis C virus infection. Gastroenterol Hepatol. 8:91–101. 2012.
14	Hézode C, Forestier N, Dusheiko G, et al; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 360:1839–1850. 2009.
15	Yee HS, Chang MF, Pocha C, et al: Update on the management and treatment of hepatitis C virus infection: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program office. Am J Gastroenterol. 107:669–689. 2012.
16	Chayama K, Hayes CN, Ohishi W and Kawakami Y: Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 48:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
17	Forestier N and Zeuzem S: Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int. 32:44–50. 2012. View Article : Google Scholar : PubMed/NCBI
18	Poordad F, Bronowicki JP, Gordon SC, et al; SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 143:608–618. 2012. View Article : Google Scholar : PubMed/NCBI
19	Chayama K, Hayes CN, Abe H, et al: IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 204:84–93. 2011. View Article : Google Scholar : PubMed/NCBI
20	Akuta N, Suzuki F, Seko Y, et al: Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 84:1097–1105. 2012. View Article : Google Scholar : PubMed/NCBI
21	Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE and Rice CM: The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem. 279:48576–48587. 2004. View Article : Google Scholar : PubMed/NCBI
22	Moradpour D, Penin F and Rice CM: Replication of hepatitis C virus. Nat Rev Microbiol. 5:453–463. 2007. View Article : Google Scholar
23	Yano Y, Seo Y, Miki A, et al: Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Int J Mol Med. 30:1048–1052. 2012.PubMed/NCBI
24	Ide Y, Zhang L, Chen M, et al: Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A. Gene. 182:203–211. 1996. View Article : Google Scholar : PubMed/NCBI
25	Tanji Y, Kaneko T, Satoh S and Shimotohno K: Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol. 69:3980–3986. 1995.
26	Vermehren J and Sarrazin C: The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 26:487–503. 2012. View Article : Google Scholar : PubMed/NCBI
27	Hayashi N, Seto C, Kato M, Komada Y and Goto S: Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroetnterol. 49:138–147. 2014.PubMed/NCBI
28	Sarrazin C, Hezode C, Zeuzem S and Pawlotski JM: Antiviral strategies in hepatitis C virus infection. J Hepatol. 56(Suppl 1): S88–S100. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chayama K, Takahashi S, Toyoda J, et al: Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 55:742–748. 2012. View Article : Google Scholar
30	Suzuki Y, Ikeda K, Suzuki F, et al: Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 58:655–662. 2013. View Article : Google Scholar : PubMed/NCBI